Inhalation of interferon significantly reduces the risk of deterioration of the new crown.

Today, British biotech company Synairgen announced that its inhaled beta interferon formulation SNG001 significantly reduces the risk of deterioration in patients with early new crowns in a stage II clinical phase.
the trial recruited 101 patients with an early (average symptoms of 9 days), moderate (needing hospitalization but no intubation) with 14 days of SNG001 and placebo for 14 days, respectively.
results SNG001 reduced the risk of deterioration by 79%, increased the recovery rate by 2-3 times, and significantly reduced breathing difficulties. sNG shares
surged 428 per cent today.
a common feature of drug source analysis of coronavirus infection is insufficient interferon secretion, not timely, which is particularly evident in the new crown.
blood analysis of critically ill patients published last week in the journal Science shows that the synthesis of IFNb and IFNa is also severely inadequate.
but the interferon response system appears to function properly, but no interferon is produced so there is no output.
interferon response gene (ISG) varies according to the selected gene, cell type, and detection technique.
an article in the journal Science Immunology last week said that isg expression, IFNI and IL6, are similar to helping, but the Science study said severe illness is lower than that of mild ISG.
interferon is the first line of defense against viral infection, and four or five of the 29 proteins expressed by the new crown have systemic functions that inhibit congenital immunity and interferon, so interferon has always been a more reliable treatment strategy.
in vitro experiments have shown that a type of interferon can indeed remove new crowns and is more effective than other coronaviruses such as SARS.
interferon not only induces many protein expression with direct antiviral activity, but also organizes the immune system to fight the virus together, so there may be more function in the patient.
a clinical study in Hong Kong a few months ago showed that injection scans of IFNb can shorten the time it takes for new crowns to turn to cast, and IFNa sprays have also shown that infection rates can be reduced.
but the innate immunoactivation agents administered by the system have systemic toxicity problems, which is also the main factor limiting TLR, STING, which promote ifNI synthesis of popular anti-cancer targets.
SNG001 is an inhaler, and the main lesions of the early stage of the new crown infection are in the lungs, which is just right for this mode of administration.
Gilead's Redsewere inhaler is also about to begin clinical trials. before the emergence of the
new crown SNG001 mainly as a preventive drug to prevent COPD patients from suddenly deteriorating due to viral infection, the new crown of the world has given this product a new use.
Today's trial, although limited in number, has significantly improved in several key indicators, and the efficacy seems to be relatively certain.
because the number of fewer indicators p-valueare to barely meet the standard, of course, even barely into the national training team also shows the ball skills.
the biggest problem in today's bulletin is that the trial's primary endpoint is not to reduce the risk of deterioration, but to compare the severity of the two groups of diseases.
SNG did not publish the results today, but said the distinction was statistically significant and was not made public because the analysis was more complex.
the number of diabetics in the other group was slightly higher, although the total number of underlying diseases was similar.
hope that the detailed results will not be discovered by accident after they are officially published.
early new crown infections have been used in the market by Redsewe until now, sNG001's data today are similar to Redsewe's in terms of reducing hospital stays.
of course these are two completely different mechanisms, one inhibits the proliferation of viruses, one accelerates virus removal, so the combined efficacy shows a greater chance of synergy.
in the treatment of hepatitis C, although IFNa itself is not effective, but with the efficacy of the mediocre ribavirin (-10% cure rate) but miraculously increased the cure rate to 50%.
the most significantly best drug for severe new crowns is dexamethasone, although it is ineffective in patients over 70.
also released data today on two new coronavirus vaccines, which appear to show some promise, both in terms of neutralizing antibody titness, T-cell activity, and tolerance.
Although there is no highly effective drug, the combination of vaccines, antiviraldrugs and immunomodulators is expected to make the new crown a low-risk disease.
.